These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 1337629)
1. Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Hollas W; Hoosein N; Chung LW; Mazar A; Henkin J; Kariko K; Barnathan ES; Boyd D Thromb Haemost; 1992 Dec; 68(6):662-6. PubMed ID: 1337629 [TBL] [Abstract][Full Text] [Related]
2. Invasion of extracellular matrix by cultured colon cancer cells: dependence on urokinase receptor display. Schlechte W; Brattain M; Boyd D Cancer Commun; 1990; 2(5):173-9. PubMed ID: 2164413 [TBL] [Abstract][Full Text] [Related]
3. Examination of the effects of epidermal growth factor on the production of urokinase and the expression of the plasminogen activator receptor in a human colon cancer cell line. Boyd D Cancer Res; 1989 May; 49(9):2427-32. PubMed ID: 2539903 [TBL] [Abstract][Full Text] [Related]
4. Determination of the effects of epidermal growth factor on urokinase secretion and urokinase receptor display in a well-differentiated human colon carcinoma cell line. Boyd D; Brattain M Cancer Res; 1989 Apr; 49(8):1948-53. PubMed ID: 2539250 [TBL] [Abstract][Full Text] [Related]
5. Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Hollas W; Blasi F; Boyd D Cancer Res; 1991 Jul; 51(14):3690-5. PubMed ID: 1648443 [TBL] [Abstract][Full Text] [Related]
6. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro. Paciucci R; Torà M; Díaz VM; Real FX Oncogene; 1998 Feb; 16(5):625-33. PubMed ID: 9482108 [TBL] [Abstract][Full Text] [Related]
7. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. Nip J; Rabbani SA; Shibata HR; Brodt P J Clin Invest; 1995 May; 95(5):2096-103. PubMed ID: 7537755 [TBL] [Abstract][Full Text] [Related]
8. Effect of hepatocyte growth factor on invasion of prostate cancer cell lines. Fujiuchi Y; Nagakawa O; Murakami K; Fuse H; Saiki I Oncol Rep; 2003; 10(4):1001-6. PubMed ID: 12792760 [TBL] [Abstract][Full Text] [Related]
9. Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: role of epigenetic mechanisms. Hagelgans A; Menschikowski M; Fuessel S; Nacke B; Arneth BM; Wirth MP; Siegert G Exp Mol Pathol; 2013 Jun; 94(3):458-65. PubMed ID: 23541763 [TBL] [Abstract][Full Text] [Related]
10. Amplification of urokinase gene in prostate cancer. Helenius MA; Saramäki OR; Linja MJ; Tammela TL; Visakorpi T Cancer Res; 2001 Jul; 61(14):5340-4. PubMed ID: 11454671 [TBL] [Abstract][Full Text] [Related]
11. A urokinase receptor mRNA binding protein-mRNA interaction regulates receptor expression and function in human pleural mesothelioma cells. Shetty S; Idell S Arch Biochem Biophys; 1998 Aug; 356(2):265-79. PubMed ID: 9705217 [TBL] [Abstract][Full Text] [Related]
12. Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin. Yoshida E; Verrusio EN; Mihara H; Oh D; Kwaan HC Cancer Res; 1994 Jun; 54(12):3300-4. PubMed ID: 8205553 [TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator and metalloprotease activities of Du-145, PC-3, and 1-LN-PC-3-1A human prostate tumors grown in nude mice: correlation with tumor invasive behavior. Wilson MJ; Sinha AA Cell Mol Biol Res; 1993; 39(8):751-60. PubMed ID: 7951414 [TBL] [Abstract][Full Text] [Related]
14. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751 [TBL] [Abstract][Full Text] [Related]
15. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87). Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639 [TBL] [Abstract][Full Text] [Related]
16. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Boyd D; Florent G; Kim P; Brattain M Cancer Res; 1988 Jun; 48(11):3112-6. PubMed ID: 2835152 [TBL] [Abstract][Full Text] [Related]
17. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas. Foca C; Moses EK; Quinn MA; Rice GE Gynecol Oncol; 2000 Nov; 79(2):244-50. PubMed ID: 11063652 [TBL] [Abstract][Full Text] [Related]
18. Decreased expression of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor in invasive cell clones derived from human prostate and breast tumor cells. Kancha RK; Stearns ME; Hussain MM Oncol Res; 1994; 6(8):365-72. PubMed ID: 7534510 [TBL] [Abstract][Full Text] [Related]
19. In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor. Mohanam S; Chintala SK; Go Y; Bhattacharya A; Venkaiah B; Boyd D; Gokaslan ZL; Sawaya R; Rao JS Oncogene; 1997 Mar; 14(11):1351-9. PubMed ID: 9178895 [TBL] [Abstract][Full Text] [Related]
20. Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo. Pakneshan P; Xing RH; Rabbani SA FASEB J; 2003 Jun; 17(9):1081-8. PubMed ID: 12773490 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]